Blackstone and TPG-backed Hologic agrees deal for precision oncology firm Reveal Genomics

Published on October 21, 2026

Barcelona-based Reveal Genomics develops genomic diagnostic tests to guide cancer treatment, including HER2DX for HER2-positive breast cancer.

The post Blackstone and TPG-backed Hologic agrees deal for precision oncology firm Reveal Genomics appeared first on PE Hub.